Abstract
3-O-Methylnaltrexone (3-MNTX), a putative antagonist of morphine-6-β-d-glucuronide (M6G) receptors, has been reported to block the behavioral effects of heroin at doses that do not block those of morphine, suggesting that M6G receptors may play a unique role in the addictive properties of heroin. This study investigated the effects of 3-MNTX in monkeys trained to discriminate i.v. heroin from vehicle or to self-administer i.v. heroin under a progressive-ratio schedule. Additional in vitro studies determined the effects of 3-MNTX and reference drugs on adenylyl cyclase activity in caudate-putamen membranes of monkeys and rats. In drug discrimination experiments, heroin, morphine, and M6G substituted for heroin in all subjects, whereas 3-MNTX substituted for heroin in one-half the monkeys tested. In these latter monkeys, the effects of 3-MNTX were antagonized by naltrexone, and pretreatment with 3-MNTX enhanced the effects of heroin, M6G, and morphine, indicative of μ-agonist activity. In monkeys showing no substitution of 3-MNTX for heroin, 3-MNTX antagonized the effects of heroin, M6G, and morphine. In self-administration experiments, heroin and 3-MNTX maintained injections per session significantly above those maintained by vehicle when the initial response requirement (IRR) was low; only heroin maintained significant self-administration when the IRR was high. In vitro, 3-MNTX inhibited adenylyl cyclase activity in both monkey and rat brain membranes. The degree of inhibition produced by 3-MNTX was less than that produced by the full agonist [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO). The results suggest that 3-MNTX functions primarily as a partial agonist at μ-receptors in monkeys and do not support a singular role for M6G receptors in the abuse-related effects of heroin.
Footnotes
-
This research was supported by U.S. Public Health Services Grants DA11928, DA11960, and RR00168. A preliminary report of these data was made at the 2001 Annual Meeting of the College on Problems of Drug Dependence.
-
DOI: 10.1124/jpet.103.060962.
-
ABBREVIATIONS: 6MAM, 6-monoacetylmorphine; M6G, morphine-6-β-d-glucuronide; M3G, morphine-3-β-d-glucuronide; 3-MNTX, 3-O-methylnaltrexone; DS, discriminative stimulus; PR, progressive-ratio; IRR, initial response requirement; FR, fixed-ratio; BP, break point; DAMGO, [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin.
- Received October 6, 2003.
- Accepted November 20, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|